咪康唑治疗癌症患者真菌感染
Miconazole therapy for treatment of fungal infections in cancer patients.
作者信息
Jordan W M, Bodey G P, Rodriguez V, Ketchel S J, Henney J
出版信息
Antimicrob Agents Chemother. 1979 Dec;16(6):792-7. doi: 10.1128/AAC.16.6.792.
The effectiveness of miconazole was evaluated in 37 documented fungal infections, 32 of which were major infections. All patients were receiving therapy for advanced malignancy, with 28 patients having acute leukemia. The overall cure rate was 41% and it was also 41% for major fungal infections. Nine of 22 patients with Candida albicans infections were cured, and 3 of 11 patients with Candida tropicalis infections were cured. A total of 183 patients who received miconazole for presumed or documented fungal infection were evaluated for toxicity. Nausea and vomiting and central nervous system toxicity were the most common side effects, occurring in 25 and 16% of the patients, respectively. Overall, the drug was tolerated well, with only four patients requiring the drug to be permanently discontinued because of toxicity.
对37例已记录的真菌感染患者评估了咪康唑的疗效，其中32例为严重感染。所有患者均接受晚期恶性肿瘤治疗，28例患者患有急性白血病。总体治愈率为41%，严重真菌感染的治愈率也为41%。22例白色念珠菌感染患者中有9例治愈，11例热带念珠菌感染患者中有3例治愈。对总共183例因疑似或已记录的真菌感染而接受咪康唑治疗的患者进行了毒性评估。恶心、呕吐和中枢神经系统毒性是最常见的副作用，分别发生在25%和16%的患者中。总体而言，该药物耐受性良好，只有4例患者因毒性需要永久停用该药物。
Zotero 插件